JP2024503924A - カリクレイン関連ペプチダーゼ２抗原結合ドメインを含む免疫コンジュゲート及びその使用 - Google Patents

カリクレイン関連ペプチダーゼ２抗原結合ドメインを含む免疫コンジュゲート及びその使用 Download PDF

Info

Publication number
JP2024503924A
JP2024503924A JP2023545254A JP2023545254A JP2024503924A JP 2024503924 A JP2024503924 A JP 2024503924A JP 2023545254 A JP2023545254 A JP 2023545254A JP 2023545254 A JP2023545254 A JP 2023545254A JP 2024503924 A JP2024503924 A JP 2024503924A
Authority
JP
Japan
Prior art keywords
binding domain
formula
immunoconjugate
independently
radioactive metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023545254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503924A5 (https=
Inventor
シェン，フェイ
マクデヴィット，テレサ
ゴールドバーグ，シャロム
ウィリー，クリステン
エム． スミス，リャン
ヴェンカタラマニ，サチャデヴィ
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2024503924A publication Critical patent/JP2024503924A/ja
Publication of JP2024503924A5 publication Critical patent/JP2024503924A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2023545254A 2021-01-27 2022-01-26 カリクレイン関連ペプチダーゼ２抗原結合ドメインを含む免疫コンジュゲート及びその使用 Pending JP2024503924A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163142147P 2021-01-27 2021-01-27
US63/142,147 2021-01-27
US202163144586P 2021-02-02 2021-02-02
US63/144,586 2021-02-02
PCT/IB2022/050673 WO2022162549A2 (en) 2021-01-27 2022-01-26 Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses

Publications (2)

Publication Number Publication Date
JP2024503924A true JP2024503924A (ja) 2024-01-29
JP2024503924A5 JP2024503924A5 (https=) 2025-01-30

Family

ID=80447388

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545254A Pending JP2024503924A (ja) 2021-01-27 2022-01-26 カリクレイン関連ペプチダーゼ２抗原結合ドメインを含む免疫コンジュゲート及びその使用

Country Status (9)

Country Link
US (1) US20250325718A1 (https=)
EP (1) EP4284446A2 (https=)
JP (1) JP2024503924A (https=)
KR (1) KR20230142482A (https=)
AU (1) AU2022213825A1 (https=)
CA (1) CA3205707A1 (https=)
IL (1) IL304656A (https=)
MX (1) MX2023008803A (https=)
WO (1) WO2022162549A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
CN109843339B (zh) 2016-06-23 2023-07-07 康奈尔大学 影响肿瘤杀伤的双重靶向构建体
JP7699542B2 (ja) 2018-11-20 2025-06-27 コーネル ユニバーシティー 放射線核種の大環状錯体およびがんの放射線療法におけるそれらの使用
BR112021022237A2 (pt) 2019-05-10 2022-03-29 Janssen Biotech Inc Queladores macrocíclicos e métodos de uso dos mesmos
BR112022001368A2 (pt) 2019-07-26 2022-05-24 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
CA3240194A1 (en) * 2021-11-09 2023-05-19 Edward Cleator Macrocyclic compounds and methods of making the same
EP4469095A1 (en) * 2022-01-26 2024-12-04 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502092A (ja) * 2002-03-08 2006-01-19 プロテイン デザイン ラブス インコーポレイティド ガン抗原ｔｍｅｆｆ２に対する抗体及びそれらの使用
JP2008546792A (ja) * 2005-06-20 2008-12-25 ピーエスエムエー ディベロップメント カンパニー，エルエルシー Ｐｓｍａ抗体薬物複合体
JP2016540503A (ja) * 2013-11-19 2016-12-28 フレダックス・アクチエボラーグ ヒト化抗カリクレイン−２抗体
WO2020229974A1 (en) * 2019-05-10 2020-11-19 Janssen Biotech, Inc. Macrocyclic chelators and methods of use thereof
WO2021019389A1 (en) * 2019-07-26 2021-02-04 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
ES2984483T3 (es) 2010-03-31 2024-10-29 Ablexis Llc Ingeniería genética de ratones para la producción de anticuerpos quiméricos
PT2931030T (pt) 2012-12-14 2020-08-03 Open Monoclonal Tech Inc Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem
WO2017087826A1 (en) 2015-11-18 2017-05-26 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
IL269763B2 (en) 2017-03-30 2024-08-01 Univ Cornell Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
JP7699542B2 (ja) 2018-11-20 2025-06-27 コーネル ユニバーシティー 放射線核種の大環状錯体およびがんの放射線療法におけるそれらの使用
WO2021060350A1 (ja) 2019-09-27 2021-04-01 株式会社Ｊ－オイルミルズ 食肉加工品の製造方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502092A (ja) * 2002-03-08 2006-01-19 プロテイン デザイン ラブス インコーポレイティド ガン抗原ｔｍｅｆｆ２に対する抗体及びそれらの使用
JP2008546792A (ja) * 2005-06-20 2008-12-25 ピーエスエムエー ディベロップメント カンパニー，エルエルシー Ｐｓｍａ抗体薬物複合体
JP2016540503A (ja) * 2013-11-19 2016-12-28 フレダックス・アクチエボラーグ ヒト化抗カリクレイン−２抗体
WO2020229974A1 (en) * 2019-05-10 2020-11-19 Janssen Biotech, Inc. Macrocyclic chelators and methods of use thereof
WO2021019389A1 (en) * 2019-07-26 2021-02-04 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. CLIN. ONCOL., vol. Vol. 38, No. 6_suppl, JPN5024009311, 2020, pages 249, ISSN: 0005765791 *
NATURE COMMUNICATIONS, vol. 9, no. 1629, JPN5024009310, 2018, pages 1 - 11, ISSN: 0005765790 *
THERANOSTICS, vol. 9, no. 8, JPN5024009312, 2019, pages 2129 - 2142, ISSN: 0005765792 *

Also Published As

Publication number Publication date
WO2022162549A3 (en) 2022-09-29
WO2022162549A2 (en) 2022-08-04
CA3205707A1 (en) 2022-08-04
AU2022213825A1 (en) 2023-09-14
US20250325718A1 (en) 2025-10-23
MX2023008803A (es) 2023-08-04
KR20230142482A (ko) 2023-10-11
IL304656A (en) 2023-09-01
EP4284446A2 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
US12453785B2 (en) Macrocyclic chelators and methods of use thereof
JP2024503924A (ja) カリクレイン関連ペプチダーゼ２抗原結合ドメインを含む免疫コンジュゲート及びその使用
US20240238461A1 (en) Macrocyclic compounds and methods of use thereof
US20250145646A1 (en) Macrocyclic compounds and diagnostic uses thereof
US20250082793A1 (en) Macrocyclic compounds and methods of making the same
US20250099635A1 (en) Iimmunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
CN116806159A (zh) 包含激肽释放酶相关肽酶2抗原结合结构域的免疫缀合物及其用途
HK40098620A (zh) 包含激肽释放酶相关肽酶2抗原结合结构域的免疫缀合物及其用途
HK40071088A (en) Macrocyclic chelators and methods of use thereof
CN118201925A (zh) 大环化合物及其制备方法
EA048132B1 (ru) Макроциклические хелаторы и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260324